Blog Archives

Axicabtagene Ciloleucel (Yescarta) gene therapy for diffuse large B-cell lymphoma

October 19, 2017 – The American  Food & Drug Administration (FDA) just approved Axicabtagene Ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

Read more ›

Tags: , , , , , , , , , , , , , ,

Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved

February 16, 2017 – The American Food & Drug Administration (FDA) just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq) is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream,

Read more ›

Tags: , , , , , , , ,

The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA

December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension,

Read more ›

Tags: , , , , , , , , , , , ,

Dulaglutide [Trulicity], a glucagon-like peptide-1 (GLP-1) receptor agonist, approved for the treatment of type 2 diabetes

September 18, 2014 – We learn today from the U.S. Food and Drug Administration (FDA) of the approval of  Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Read more ›

Tags: , , , , ,

US: Approval of Alglucosidase Alfa [Lumizyme] to treat Pompe disease expanded to patients of all ages

August 1. 2014 – The U.S. Food and Drug Administration today announced the approval of Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than 8 years of age. In addition,

Read more ›

Tags: , , , ,

FDA approves Albiglutide [Tanzeum] to treat type 2 diabetes

April 16, 2014 – The U.S. Food and Drug Administration (FDA)  yesterday  approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Type 2 diabetes affects approximately 24 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States.

Read more ›

Tags: , , , , , , , , ,

Belatacept [Nulojix]: Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML)

July 7, 2011 – Bristol-Myers Squibb (BMS) today informed healthcare professionals about a REMS (Risk Evaluation and Mitigation Strategy) that is required for Belatacept [Nulojix] to ensure that the benefits of Belatacept [Nulojix] outweigh the risks of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML), both of which can be fatal.

Read more ›

Tags: , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Tick, tock: How stress speeds up your chromosomes' aging clock December 5, 2019
    Ageing is an inevitability for all living organisms, and although we still don't know exactly why our bodies gradually grow ever more decrepit, we are starting to grasp how it happens.
  • Genome testing for siblings of kids with autism may detect ASD before symptoms appear December 5, 2019
    One of the key priorities of interventions for autism spectrum disorder (ASD) is starting early, with some evidence showing infants as young as seven months old could benefit. Yet, most children in North America aren't diagnosed with ASD until they're over four years of age. New research led by The Hospital for Sick Children (SickKids) […]
  • 2019: the year gene therapy came of age December 5, 2019
    In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering—by editing her genome.
  • Scientists create 'epigenetic couch potato' mouse December 4, 2019
    Why is it that some people love to exercise, and others hate it? Most people would assume it's all due to genetics, but a new Baylor College of Medicine led study in mice shows for the first time that a different molecular level of regulation—epigenetics—plays a key role in determining one's innate drive to exercise. […]
  • Human genetic enhancement might soon be possible—but where do we draw the line? December 4, 2019
    The first genetically edited children were born in China in late 2018. Twins Lulu and Nana had a particular gene—known as CCR5—modified during embryonic development. The aim was to make them (and their descendants) resistant to HIV. By some definitions, this would be an example of human enhancement.
Top